Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC
Clinical trial NCT03439735 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03439735
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-20
- Primary completion
- 2027-08-01
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.